Hennion & Walsh Asset Management’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$337K Buy
+906
New +$271K 0.01% 833
2025
Q3
Sell
-3,253
Closed -$447K 959
2025
Q2
$447K Sell
3,253
-6,952
-68% -$1.02M 0.02% 707
2025
Q1
$1.84M Sell
10,205
-3,473
-25% -$584K 0.08% 295
2024
Q4
$2.14M Sell
13,678
-232
-2% -$41.2K 0.1% 272
2024
Q3
$2.53M Sell
13,910
-7,740
-36% -$1.49M 0.12% 220
2024
Q2
$3.98M Sell
21,650
-11,504
-35% -$1.93M 0.2% 117
2024
Q1
$5.9M Buy
33,154
+1,756
+6% +$244K 0.32% 62
2023
Q4
$3.9M Sell
31,398
-19,423
-38% -$2.15M 0.22% 110
2023
Q3
$5.9M Buy
50,821
+1,139
+2% +$139K 0.38% 45
2023
Q2
$5.83M Buy
49,682
+4,447
+10% +$454K 0.35% 62
2023
Q1
$3.62M Buy
45,235
+32
+0.1% +$2.51K 0.22% 118
2022
Q4
$3.58M Buy
45,203
+4,547
+11% +$337K 0.22% 116
2022
Q3
$2.83M Buy
40,656
+7,663
+23% +$554K 0.19% 144
2022
Q2
$2.17M Buy
32,993
+9,625
+41% +$599K 0.13% 191
2022
Q1
$1.55M Buy
23,368
+9,231
+65% +$576K 0.08% 257
2021
Q4
$989K Buy
+14,137
New +$823K 0.05% 360

Other funds holding KRYS

Hennion & Walsh Asset Management's KRYS Position: Q2 2026 in Review

Hennion & Walsh Asset Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 906 shares worth $337K. The stake represents 0.01% of the portfolio and ranks #833 among its holdings. This is a return to the name: Hennion & Walsh Asset Management previously reported a position in KRYS as recently as Q2 2025.

Hennion & Walsh Asset Management first reported a position in KRYS in Q4 2021 and has held it in 16 quarters since. The position peaked at $5.9M in Q1 2024. 34 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Hennion & Walsh Asset Management held 906 shares of Krystal Biotech worth $337K as of Q2 2026.
  • Krystal Biotech was a new Hennion & Walsh Asset Management position in Q2 2026.
  • Krystal Biotech made up 0.01% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #833 holding.
  • Hennion & Walsh Asset Management first reported a position in Krystal Biotech in Q4 2021 and has held it in 16 quarters since.
  • Hennion & Walsh Asset Management's Krystal Biotech position peaked at $5.9M in Q1 2024.
  • 34 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.